|
|
||||||||
Papers In Press, published online ahead of print February 11, 2006
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Department of Medicine/Division of Medical Genetics, University of Washington Medical Center, Seattle, WA 98195-7720
Corresponding Author: pair{at}u.washington.edu
Paraoxonase (PON1) activity is consistently predictive of vascular disease, although genotype at four functional PON1 polymorphisms is not. To address this inconsistency we investigated the role of all common PON1 genetic variability, as measured by tagSNPs, in predicting PON1 activity for phenylacetate hydrolysis, low density lipoprotein (LDL) susceptibility to oxidation ex vivo, plasma homocysteine (Hcy) levels and carotid artery disease (CAAD) status. The biological goal was to establish if additional common genetic variation beyond consideration of the four known functional SNPs improves prediction of these phenotypes. PON2 and PON3 tagSNPs were secondarily evaluated. Expanded analysis of an additional 26 tagSNPs found evidence of previously undescribed common PON1 polymorphisms that affect PON1 activity independently of the four known functional SNPs. PON1 activity was not significantly correlated with LDL oxidative susceptibility, but genotypes at the PON1-108 promoter polymorphism and several other PON1 SNPs were. Neither PON1 activity nor PON1 genotype was significantly correlated with plasma Hcy levels. This study revealed previously undetected common functional PON1 polymorphisms that explain 4% of PON1 activity and a high rate of recombination in PON1, but the sum of the common PON1 locus variation does not explain the relationship between PON1 activity and CAAD.
This article has been cited by other articles:
![]() |
P. W. Connelly, G. F. Maguire, C. M. Picardo, J. F. Teiber, and D. Draganov Development of an immunoblot assay with infrared fluorescence to quantify paraoxonase 1 in serum and plasma J. Lipid Res., January 1, 2008; 49(1): 245 - 250. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Cronin, M. J Greenway, J. H M Prehn, and O. Hardiman Paraoxonase promoter and intronic variants modify risk of sporadic amyotrophic lateral sclerosis J. Neurol. Neurosurg. Psychiatry, September 1, 2007; 78(9): 984 - 986. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |